CBIO News and Press, Catalyst Biosciences Inc. From 02/28/23

South Korea's GC Biopharma is acquiring three programs related to orphan blood disorders from Catalyst Biosciences ( NASDAQ: CBIO ). The agreement will bring to GC Biopharma programs, including Marzeptacog alfa (MarzAA), an engineered factor VIIa which is ready for phase 3 d...

NEW YORK, NY / ACCESSWIRE / January 5, 2023 / Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Trean Insurance Group, Inc. (NASDAQ:TI...

Clinical-stage biotech Catalyst Biosciences ( NASDAQ: CBIO ) added ~6% pre-market Tuesday after the company announced several transactions to highlight the completion of the first steps in its reverse merger plan. Accordingly, Catalyst ( CBIO ) has inked agreements for the sal...

Acquires F351, a Phase 3 Drug to Treat Fibrosis Will Acquire Controlling Interest in Continent, a China-Based Commercial Pharma Company, from the GNI Group in Subsequent Transaction Announces $7.5 Million Special Dividend and Contingent Value Right (CVR) CBIO Stockholder M...

Summary Today is a great time to invest for the long run, though the market may very likely experience more volatility before once again resuming its march higher. We expect meaningful market share gains from most if not all of our investments. Returns from here will be powere...

SOUTH SAN FRANCISCO, Calif., Sept. 01, 2022 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ: CBIO) (“Catalyst,” the “Company” or “we”) today announced that the ex-dividend date for the special, one-time cash dividend of $1.43 per share to hol...

Catalyst Biosciences ( NASDAQ: CBIO ) declares $1.43/share one-time special dividend . Payable Sept. 20; for shareholders of record Sept. 6; ex-div Sept. 2. See CBIO Dividend Scorecard, Yield Chart, & Dividend Growth. For further details see: Catalyst...

SOUTH SAN FRANCISCO, Calif., Aug. 25, 2022 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ: CBIO) (“Catalyst,” the “Company” or “we”) today announced that the Board of Directors has declared a special, one-time cash dividend of $1.43 per shar...

SOUTH SAN FRANCISCO, Calif., Aug. 19, 2022 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ: CBIO) (“Catalyst,” the “Company” or “we”) today announced that JDS1, LLC, one of the Company’s stockholders, has dismissed its lawsuits against...

Catalyst Biosciences press release ( NASDAQ: CBIO ): Q2 GAAP EPS of $1.64. At the end of the second quarter, the Board expected the total amount of cash to be distributed to stockholders to be up to $65.0 million in one or more distributions Cash and cash equivalents a...